NEW YORK, March 27, 2017 /PRNewswire/ --
Pre-market today, Stock-Callers.com has initiated reports coverage on Actinium Pharmaceuticals Inc. (NYSEMKT: ATNM), Eleven Biotherapeutics Inc. (NASDAQ: EBIO), Neuralstem Inc. (NASDAQ: CUR), and Aptose Biosciences Inc. (NASDAQ: APTO). According to an article of ETF Trends, the iShares Nasdaq Biotechnology ETF is higher by nearly 12% this year, a sign that biotech stocks are on the mend after being one of last year's most noticeable laggards. Register now and get full and free access to our downloadable research reports on these stocks at:
Last Friday, shares in New York headquartered Actinium Pharmaceuticals Inc. ended the session 1.38% lower at $1.43. The stock recorded a trading volume of 329,614 shares. The Company's shares have advanced 0.70% in the last one month, 45.46% over the previous three months, and 63.43% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 10.92% and 3.68%, respectively. Furthermore, shares of Actinium Pharma, which develops targeted payload immunotherapeutics for the treatment of advanced cancers, have a Relative Strength Index (RSI) of 56.26.
On March 16th, 2017, Actinium Pharmaceuticals announced that it is a sponsor of Oncology Meeting Innovations' 4th Annual Summit on Hematologic Malignancies, which is being held March 30th to April 02nd, 2017 at the Fairmont Chateau Whistler in British Columbia, Canada. Dr. John Pagel of the Swedish Cancer Institute will speak in the Emerging Drugs Showcase session titled, "Radioimmunotherapy in AML: Iomab-B and Actimab-A," on Saturday April 01st, 2017. Access our complete research report on ATNM for free at:
Cambridge, Massachusetts-based Eleven Biotherapeutics Inc.'s stock finished 5.79% higher at $2.01. A total volume of 3.69 million shares was traded, which was above their three months average volume of 435,940 shares. The Company's shares have gained 0.50% in the previous three months and 5.24% since the start of this year. The stock is trading below its 50-day moving average by 2.20%. Moreover, shares of Eleven Biotherapeutics, which focuses on the development of novel therapies based upon tumor targeting antibody fragments genetically fused to a cytotoxic protein payload called Targeted Protein Therapeutics, have an RSI of 52.36.
On March 20th, 2017, Eleven Biotherapeutics announced that Stephen Hurly, President and CEO, will present a Company overview at Oppenheimer's 27th Annual Healthcare Conference in New York on Tuesday, March 21st, 2017 at 9:10 a.m. ET. A live webcast can be accessed from the Investors & Media section of the Company's website. The complimentary research report on EBIO can be downloaded at:
Shares in Germantown, Maryland headquartered Neuralstem Inc. closed the day 0.92% higher at $5.50. The stock recorded a trading volume of 82,319 shares. The Company's shares have surged 48.65% in the last month, 41.03% over the previous three months, and 56.70% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 34.69% and 46.41%, respectively. Moreover, shares of Neuralstem, which focuses on the research, development, and commercialization of central nervous system therapies based on its proprietary human neuronal stem cells and stem-cell derived small molecule compounds, have an RSI of 62.26.
On March 23rd 2017, Neuralstem reported its financial results for Q4 2016 and year ended December 31st, 2016. Cash, cash equivalents, and short-term investments on hand were approximately $20.2 million; net loss was approximately $21.1 million, or $2.53 per share on a split-adjusted basis; and research and development expenditures increased by approximately $0.5 million at $13.2 million on December 31st, 2016. Register for free on Stock-Callers.com and get access to the latest PDF format report on CUR at:
Mississauga, Canada headquartered Aptose Biosciences Inc.'s shares recorded a trading volume of 69,761 shares last Friday. The stock closed 0.88% higher at $1.14. The Company's shares have advanced 0.88% in the past month, and are trading 1.26% above their 50-day moving average. Additionally, shares of Aptose Biosciences, which discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada, have an RSI of 51.09. Download your free research report on APTO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA